Forbes Highlights Historic FDA Approval of Narcolepsy Type 1 Drug Orzeyful

Project Sleep is excited to report that Forbes Health published an article covering the FDA’s approval of oveporexton (commercial name Orzeyful), the first approved therapy designed to target the underlying biological cause of narcolepsy type 1. This marks a milestone that people with narcolepsy have been anticipating for decades, and Project Sleep is grateful to see national media spotlighting the significance of this breakthrough.

Forbes reporter Claire Wolters spoke with sleep experts and patient advocates, including Project Sleep’s President and CEO Julie Flygare, who shared her perspective as both a leader in the sleep advocacy space and someone living with narcolepsy type 1. Flygare noted that the orexin pathway was discovered less than 30 years ago, and seeing that discovery lead to a new treatment approach represents a moment of real progress for the community.

It’s just a little bit less than 30 years ago that the orexin pathway was discovered. For that to lead to a whole new treatment modality is exciting for those of us that live with type 1 narcolepsy.”

– Julie Flygare, JD
via Forbes Health

The Forbes Health article explains how oveporexton differs from previous medications. Historically, narcolepsy treatments have focused on managing symptoms through stimulants or sedatives. Oveporexton works by activating orexin signaling, which is central to regulating sleep and wakefulness. Forbes highlights expert opinions that this mechanism may make it a more targeted and potentially more effective option.

Why Forbes’ Narcolepsy Coverage Matters

Forbes’ coverage brings national attention to the importance of advancing narcolepsy research and treatment. At Project Sleep, we believe that accurate reporting and patient‑centered storytelling are essential for reducing stigma and improving understanding of sleep disorders. We appreciate Forbes for elevating this conversation and for including the voices of people directly affected by narcolepsy.

ORZEYFUL (oveporexton) FDA Approval: The First Orexin Agonist for Narcolepsy

Orzeyful is expected to become available by November 2026. Project Sleep will continue to share updates and resources as more information emerges. For now, we celebrate this meaningful step forward and remain committed to advancing education, awareness, research, and advocacy so that more people can access timely diagnosis, support, and emerging treatment options. Learn more about the first orexin agonist for narcolepsy.

More Narcolepsy News